New Hepatitis C Medications

Several new groundbreaking medications got FDA approval in the last 12 months, most of which do not require interferon or ribavirin - compounds that many patients try to avoid due to their harsh side effects.

Below you will find the most important new drugs that Dr. Ruane is prescribing to his patients.



Harvoni is a once-daily single-tablet regimen for HCV GT 1 patients.

HARVONI is the first and only Interferon- and Ribavirin-free regimen available in one tablet taken once a day

  • HARVONI is IFN- and RBV-free for GT 1 treatment-naïve and treatment-experienced patients with or without cirrhosis, regardless of  GT 1a or 1b subtype
  • Each HARVONI tablet contains 90 mg of ledipasvir and 400 mg of sofosbuvir
  • Relapse rates are affected by baseline host and viral factors and differ between treatment durations for certain subgroups
  • No dose adjustments are required based on advanced age, mild or moderate renal impairment, or mild, moderate, or severe hepatic impairment. The safety and efficacy of HARVONI have not been established in patients with decompensated cirrhosis
  • No dose recommendation can be given for patients with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2) or with end stage renal disease (ESRD) due to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite

Reference: HARVONI US full Prescribing Information. Gilead Sciences, Inc. Foster City, CA. March 2015.



SOVALDI is a prescription medicine used with other antiviral medicines to treat chronic (lasting a long time) hepatitis C infection in adults. SOVALDI should not be taken alone. It is not known if SOVALDI is safe and effective in children under 18 years of age.

SOVALDI, as part of a combination therapy, has been shown to work for genotypes 1, 2, 3, and 4 in just 12 or 24 weeks, depending on your genotype. (Results are measured 3 months after treatment is completed.)

SOVALDI is one pill, taken once daily, as part of a combination therapy

SOVALDI combination therapy is the first all-oral treatment for genotypes 2 and 3

SOVALDI is sofosbuvir—a breakthrough medicine that directly targets the Hep C virus



VIEKIRA PAK™ (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) is a prescription medicine used with or without ribavirin to treat adults with genotype 1 chronic (lasting a long time) hepatitis C (hep C) virus infection, including people who have a certain type of cirrhosis (compensated). VIEKIRA is not for people with advanced cirrhosis (decompensated).

  • In phase 3 clinical trials, viekira pak cured 95-100 percent of hepatitis c patients, with less than 2 percent of patients experiencing virological failure
  • Tolerability profile shows more than 98 percent of patients completed a full course of therapy
  • All-oral interferon-free regimen also approved for hcv/hiv-1 co-infection and patients who have undergone a liver transplant



OLYSIO® (simeprevir) is a prescription medicine used with other antiviral medicines (sofosbuvir or peginterferon and ribavirin) to treat genotype 1, chronic (lasting a long time) hepatitis C infection in adults.